# JP-1366 20mg Versus Esomeprazole 40mg in Patients With Erosive Esophagitis

> **NCT05443984** · PHASE3 · COMPLETED · sponsor: **Onconic Therapeutics Inc.** · enrollment: 300 (actual)

## Conditions studied

- Erosive Esophagitis

## Interventions

- **DRUG:** JP-1366 20mg
- **DRUG:** Esomeprazole 40mg

## Key facts

- **NCT ID:** NCT05443984
- **Lead sponsor:** Onconic Therapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-01-17
- **Primary completion:** 2023-01-05
- **Final completion:** 2023-01-05
- **Target enrollment:** 300 (ACTUAL)
- **Last updated:** 2024-08-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05443984

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05443984, "JP-1366 20mg Versus Esomeprazole 40mg in Patients With Erosive Esophagitis". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT05443984. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*